GSK secures US approval for hepatitis B drug Hibsago
21st Oct 2026 07:19
(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration had approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B in adults without cirrhosis, marking the first approval of an antisense oligonucleotide for the disease.
Read moreGSK's Ris‑Rez shows 61pc response rate in early lung cancer study
19th Oct 2026 09:05
(Sharecast News) - Drugmaker GSK reported new early‑stage global data for risvutatug rezetecan (Ris‑Rez), an experimental cancer treatment being tested in patients with relapsed small‑cell lung cancer.
Read moreBerenberg upgrades GSK to 'buy', raises target price
15th Sep 2026 07:24
(Sharecast News) - Analysts at Berenberg upgraded drugmaker GSK from 'hold' to 'buy' on Tuesday and lifted their target price on the stock from £20 to £22, saying recent business‑development activity and pipeline momentum had strengthened the firm's long‑term growth outlook and left its valuation discount looking excessive.
Read moreGSK acquires global rights to multiple myeloma asset from Chimagen Biosciences
15th Sep 2026 07:23
(Sharecast News) - Drugmaker GSK said on Tuesday that it would pay up to $750m to acquire full global rights to a trispecific T‑cell engager for multiple myeloma from privately held biotechnology company Chimagen Biosciences.
Read moreGSK highlights pipeline momentum with Ris‑Rez phase III success, Jideytro first‑line efficacy
14th Sep 2026 07:33
(Sharecast News) - Drugmaker GSK reported two major advances in its oncology pipeline on Monday, as new data showed its B7‑H3 antibody‑drug conjugate Ris‑Rez delivered a significant survival benefit in relapsed small cell lung cancer, while registrational results for Jideytro supported a potential move into first‑line ROS1‑positive non‑small cell lung cancer.
Read moreGSK gets Japanese approval for new ready‑to‑use shingles vaccine format
10th Sep 2026 07:07
(Sharecast News) - Drugmaker GSK said on Thursday that Japan's Ministry of Health, Labour and Welfare has approved a prefilled syringe version of its shingles vaccine Shingrix, offering a simpler, ready‑to‑use presentation for healthcare professionals.
Read moreGSK advances mRNA flu shot after Phase II success
1st Sep 2026 08:32
(Sharecast News) - Drugmaker GSK said on Tuesday that it will move its mRNA seasonal flu vaccine candidate into Phase III after reporting positive Phase II results at the OPTIONS XIII influenza conference.
Read moreGSK notches major regulatory milestones in Japan and US
24th Aug 2026 07:10
(Sharecast News) - Drugmaker GSK notched two major regulatory milestones on Monday, with Japan granting the first global approval for its hepatitis B therapy Hibsago and US regulators accepting a priority review for Jemperli in previously untreated locally advanced rectal cancer.
Read moreGSK secures EMA review for single‑dose Bexsero booster
20th Jul 2026 07:09
(Sharecast News) - Drugmaker GSK said on Monday that the European Medicines Agency had accepted its submission to update the label for its Bexsero asset, allowing for a single‑dose booster in people aged 10 and over who were previously vaccinated in childhood.
Read moreGSK shares fall as cough drug development axed
17th Jul 2026 11:29
(Sharecast News) - Shares in GSK fell sharply on Friday after the pharma titan announced it was stopping the development of a refractory chronic cough drug after unsuccessful results late-stage clinical trial.
Read moreGSK rectal cancer drug shows positive result in key trial
13th Jul 2026 07:03
(Sharecast News) - A treatment for rectal cancer being developed by GSK has shown positive results in interim testing, the pharma giant announced on Monday.
Read moreGSK hails 'milestone' drug trial results in China
10th Jul 2026 11:54
(Sharecast News) - A targeted lung cancer treatment developed by GSK has shown promising results in the latest trials in China, the pharma blue chip confirmed on Friday.
Read moreGSK's momelotinib receives orphan drug designation from US and EU watchdogs
12th Jun 2026 08:17
(Sharecast News) - Drugmaker GSK said on Friday that its JAK inhibitor momelotinib has been granted orphan drug designation by both the US Food and Drug Administration and the European Medicines Agency for the treatment of VEXAS syndrome, a rare and severe autoinflammatory condition with no approved therapies.
Read moreGSK to buy Boston-based biopharmaceutical firm Nuvalent for $10.6bn
9th Jun 2026 07:38
(Sharecast News) - GSK said on Tuesday that it has agreed to buy Boston-based oncology-focused biopharmaceutical firm Nuvalent for $10.6bn (£7.9bn).
Read moreTrials show GSK drug cures hepatitis B in nearly 20% of patients
28th May 2026 14:19
(Sharecast News) - GSK said on Thursday that late-stage trial results for its experimental drug for chronic hepatitis B, bepirovirsen, showed that it helped nearly one in five patients to achieve a functional cure.
Read more